ACIU AC Immune SA

11.55
-1  -4%
Previous Close 12.07
Open 12.04
Price To book 4.15
Market Cap 572.22M
Shares 49,543,000
Volume 47,260
Short Ratio 24.91
Av. Daily Volume 47,869

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiation announced February 28, 2017.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 trial to commence 2017. IPO September 23, 2016.
ACI-35 (anti-tau vaccine)
Alzheimer’s disease
Phase 1/2 ongoing. IPO September 23, 2016. Decision on future trials due within next few months - as of March 17, 2017.
ACI-24 (anti-Abeta vaccine)
Alzheimer’s disease
Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 1
Alzheimer’s disease

Latest News

  1. AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE
  2. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017
  3. Roche to start new trial of AC Immune drug against Alzheimer's
  4. AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
  5. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017
  6. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 5, 2017
  7. AC Immune SA – Value Analysis (NASDAQ:ACIU) : December 23, 2016
  8. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : December 22, 2016
  9. Here is What Hedge Funds Think About AC Immune Ltd (ACIU)
  10. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : December 12, 2016
  11. Astra, Lilly stick with Alzheimer's approach despite setback
  12. Astra, Lilly stick with Alzheimer's approach despite setback
  13. AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
  14. AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
  15. Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
  16. AC Immune SA announces results of annual general meeting
  17. AC Immune SA Reports Third Quarter 2016 Results
  18. Apptio and AC Immune Get Mixed Post-IPO Analyst Coverage at End of Quiet Period
  19. Alzheimer's Remains a Top Priority for Big Pharma
  20. AC Immune SA: Price momentum supported by strong fundamentals